Calzone, Wendy L., Celso Silva, David L. Keefe, and Nina S. Stachenfeld. Progesterone does not alter osmotic regulation of AVP. Am J Physiol Regulatory Integrative Comp Physiol 281: R2011-R2020, 2001.-To test the hypothesis that progesterone, independent of estrogen, decreases the plasma osmotic threshold for arginine vasopressin (AVP) release and thirst onset, we compared AVP and thirst responses to hypertonic saline infusion (HSI) during administration of oral contraceptives (OCs) containing progesterone (OCP) with responses to infusion of OCs containing progesterone and estrogen (OCEP). Eight women (29 Ϯ 2 yr) were infused with 3% NaCl (120 min, 0.1 ml ⅐ kg body wt Ϫ1 ⅐ min
) and consumed fluid (90 min, 15 ml/kg body wt) in the early follicular and midluteal phases of a 28-day menstrual cycle and also after 4 wk of OCP and after 4 wk of OCEP in a randomized crossover design. Baseline plasma osmolality (P osm) was lower in the luteal phase (280 Ϯ 1 mosmol/kgH2O) and during OCEP (283 Ϯ 1 mosmol/kgH2O) than in the follicular phase (286 Ϯ 1 mosmol/kgH 2O, P Ͻ 0.05) but was unaffected by OCP (284 Ϯ 1 mosmol/kgH2O). Posm remained lower in the follicular phase than in the luteal phase and with OCEP throughout the first 50 min of HSI. The mean abscissal plasma AVP concentration-P osm intercept was unaffected by OCP (267 Ϯ 1 mosmol/kgH 2O) but was greater in the follicular phase (273 Ϯ 2 mosmol/kgH2O) than in the luteal phase (266 Ϯ 4 mosmol/kgH 2O) and with OCEP (268 Ϯ 2 mosmol/kgH2O, P Ͻ 0.05). There were no differences in osmotic thresholds for thirst onset across experimental days. Despite the lower osmotic threshold for AVP release during the luteal phase and with OCEP, fluid balance, renal free water clearance, and Na ϩ regulation during HSI were unaffected by menstrual phase or OC treatment, indicating a lower osmotic operating point for body water balance. OCP did not affect osmotic AVP regulation, suggesting that progesterone does not affect osmotic fluid regulation through a mechanism independent of estrogen. body fluid regulation; estrogen; arginine vasopressin; osmolality; thirst; oral contraceptives HIGH PLASMA ESTROGEN AND PROGESTERONE levels can lead to fluid retention (9, 28, 32, 33, 36) , hypertension (20) , and edema (21, (32) (33) (34) . One proposed mechanism for these changes in body fluid regulation may be due to changes in the osmotic regulation of arginine vasopressin (AVP) and thirst sensation (27, 35, 37) . Studies using hypertonic saline infusion (HSI) have demonstrated a lower osmotic threshold for AVP release when plasma estrogen and progesterone are elevated, such as during the luteal phase of the menstrual cycle (27, 37) and late pregnancy (9) . In a recent study using dehydration, we demonstrated that this shift in osmotic stimulation of AVP and thirst occurs with no change in body fluid balance, indicating a downward resetting of the osmoreceptors (30) .
These changes in body fluid regulation are usually attributed to estrogen (1, 2, 6, 25) . Progesterone may also have independent effects on water regulation, however. Water retention and edema occur during early pregnancy (9) and during use of oral contraceptives containing progesterone only (OCP) (30) ; under both conditions, progesterone is elevated without elevations in estrogen. Progesterone can influence neuronal function in the hypothalamus (10) , and progesterone receptors are found in the paraventricular nucleus (3), a primary area involved in AVP synthesis and release. In young women taking OCP, we found a small reduction in the osmotic thresholds for AVP release and thirst onset during exercise-induced dehydration (30) . However, this shift may have been influenced by exercise effects (14) or plasma volume (PV) loss that occurs concomitantly with the increases in plasma osmolality (P osm ) during dehydration (23) .
The purpose of this study was to determine progesterone effects on osmotic regulation of AVP release and thirst sensation, as well as the impact of estrogen on those effects. To this end, we administered oral contraceptives containing estrogen and progesterone (OCEP) or OCP to young women and evaluated their responses to HSI (3% NaCl). HSI provides a strong osmotic stimulus but without the confounding effects of exercise and PV loss. OCEP agents deliver pharmacological levels of estrogen and progesterone, while OCP pills contain no estrogen. Thus these two oral contraceptive preparations differ significantly in their estrogen and progesterone activity, providing the appropriate conditions in which to isolate the effects of progesterone on body fluid and Na ϩ regulation. We hypothesized that OCP pills would reduce the threshold for osmotic AVP release and thirst sensation in response to HSI, as would OCEP pills. Consideration of PV and the effect of arterial pressure is essential for a complete evaluation of body fluid regulation, so we also determined the effects of our oral contraceptive regimen on Na ϩ regulation and the Na ϩ -regulating hormones. Finally, we measured plasma cortisol concentration (P [Cort] ) during the infusion to evaluate potential stress responses to the intense thirst induced by HSI.
METHODS

Study Design
Subjects were nine healthy nonsmoking women (age 29 Ϯ 2 yr, range 22-35 yr) with no contraindications to oral contraceptive use. The subjects underwent medical and gynecological examinations and provided written confirmation of a negative Papanicolaou smear within 1 yr of being admitted to the study. The subjects gave written informed consent to participate in the study, which had prior approval by the Human Investigations Committee of Yale University School of Medicine.
The study design employed four HSI tests, which included an infusion conducted in the early follicular phase, 2-4 days after the beginning of menstrual bleeding (low estrogen and progesterone), and an infusion in the midluteal phase, 7-9 days after the luteinizing hormone peak (high estrogen and progesterone). Each woman tested her urine using an ovulation prediction kit (OvuQuick, Quidel, San Diego, CA) to determine the monthly peak in luteinizing hormone, which occurs ϳ48 h before ovulation. After completing the two baseline tests, the women again underwent HSI after 4 wk of OCEP or OCP treatment (single-blind, random assignment). After a 4-wk "washout" period, the subjects crossed over to the other pill treatment. During OCEP, subjects received 0.035 mg of ethinyl estradiol and 1 mg of the progestin norethindrone daily. During OCP, subjects received 1 mg/day of the progestin norethindrone. To verify phase of the menstrual cycle, plasma levels of estrogen and progesterone were assessed from the baseline blood sample before infusion.
HSI Protocol
For each experiment, the subjects arrived at the laboratory at ϳ8 AM, after having eaten a light (ϳ300 kcal) breakfast, having refrained from alcohol or coffee for the previous 12 h, and having drunk 10 ml H 2O/kg body wt that morning before arriving at the laboratory.
On reporting to the laboratory, the subjects voided their bladders and were weighed to the nearest 10 g on a beam balance. The subjects were then seated in a semirecumbent position for a 60-min control period in an environmental chamber (27°C, 30% relative humidity) to ensure a steady state in PV and plasma constituents. During this control period, a 20-gauge Teflon intravenous catheter was placed in an antecubital or forearm vein in each arm with a heparin block (20 U/ml) to maintain catheter patency. A blood pressure cuff was positioned for automatic readings by a sphygmomanometric device (Colin Medical Instruments, Komaki, Japan) to monitor changes in blood pressure. A three-lead electrocardiogram (Colin Medical Instruments) provided continuous heart rate monitoring.
At the end of the control period, a baseline blood sample was taken, thirst perception was assessed, and a urine sample was collected. After these baseline samples, 3.0% NaCl was infused at 0.1 ml ⅐ kg body wt Ϫ1 ⅐ min Ϫ1 for 120 min. Blood was sampled at 10, 20, 30, 40, 50, 60, 75, 105 , and 120 min during the infusion. After the infusion, the subject rested seated for the next 120 min. This recovery period consisted of a 30-min rest period followed by a 30-min drinking period (15 ml/kg body wt of water) followed by another 60-min rest period. Blood was sampled at 30, 90, and 120 min of recovery, and an extra 5 ml of blood were drawn at 10-min intervals during the final 30 min of recovery for PV determination (Evans blue dye; see Blood Volume). In total, 200 ml of blood were drawn from each subject during each experiment. Urine was collected at baseline, immediately after infusion, and 60 min after the drinking period. Thirst perception was assessed at all blood sampling times. The subjects were weighed before and at the end of the infusion period, after the drinking period, and at the end of the protocol. Blood pressure and heart rate were recorded every 15 min throughout infusion and every 30 min after infusion.
All blood samples were analyzed for hematocrit (Hct), hemoglobin (Hb), total protein (TP), plasma osmolality (P osm), plasma concentration of creatinine (P were measured by radioimmunoassay. P [AVP] was determined by radioimmunoassay after extraction from plasma by the methods described by Freund et al. (12, 13) on octadecylsilane cartridges (Sep-Pak C18, Waters Associates, Needham, MA). Extracted samples were assayed using a disequilibrium assay with the extracts incubated with the antiserum at 4°C for 72 h followed by the addition of 125 I-AVP (New England Nuclear, Boston, MA). Bovine albumin-coated charcoal was used for separation of free and antibody-bound labeled AVP. This assay is highly specific for AVP with the antiserum prepared against a lysine vasopressin-thyroglobin conjugate and has a sensitivity of 0.6 pg/ml. The extraction recovery was 87%.
Intra-and interassay coefficients of variation for the midrange standards were, respectively, as follows: 7.1% and 10.7% for P[AVP] (3.1 pg/ml), 3.6% and 4.5% for P[Cort] (12.1 g/dl; Diagnostic Products, Los Angeles, CA), 2.8% and 5.0% for PRA (4.8 ng ⅐ ml ANG Ϫ1 ⅐ h Ϫ1 ; Immuno Biological Laboratories), 3.8% and 5.2% for P [Ald] (181 pg/ml; Diagnostic Products), 6.0% and 8.2% for P [ANP] (61.8 pg/ml; Diasorin, Stillwater, MN), 5.6% and 8.3% for P[E 2 ] (81 pg/ml; Diagnostic Products), and 2.1% and 2.7% for P [P 4 ] (1.5 ng/ml; Diagnostic Products).
Blood Volume
Absolute blood volume was measured by dilution of a known amount of Evans blue dye. An accurately determined volume of dye (by weight, since the specific density is 1.0) was injected into an arm vein, and a blood sample was taken at 10, 20, and 30 min for determination of dilution after complete mixing had occurred (10 min). Blood was also sampled at 20 and 30 min to ensure that complete mixing had occurred by the 10-min sample. If not, the 20-min sample was used for analysis. However, if complete mixing had not occurred by the 20-min sample, the blood volume measurement was not used. PV was determined from the product of the concentration and volume of dye injected divided by the concentration in the plasma after mixing, taking into account 1.5% lost from the circulation within the 10 min. Blood volume was calculated from PV and Hct concentration, corrected for peripheral sampling.
Thirst Ratings
Perception of thirst was assessed by asking the subject to make a mark on a line rating scale in response to the question, "How thirsty do you feel now?" The line is 175 mm long and is marked "not at all" on one end and "extremely thirsty" at the 125-mm point. The subjects could mark beyond the "extremely thirsty" point if they wished and could even extend the line if they felt it was necessary. This method was developed by Marks et al. (18) and has been used with great success in the evaluation of several sensory systems. We have found an extraordinarily good relationship between the perception of thirst and P osm during HSI and dehydration in young volunteers (29, 30) .
Calculations
Changes in PV were estimated from changes in Hct and Hb concentration from the baseline sample according to the following equation (17) 
where subscripts a and b denote measurements at time a and before HSI, respectively.
We used the pre-HSI Hb concentration and Hct to estimate the baseline PV from the Evans blue dye measurement at the end of the experiment.
Fractional excretions of water (FE H 2 O) and Na ϩ (FENaϩ) were calculated from the following equations
where the subscript f is glomerular filtrate, UV is urine flow rate, and S[Naϩ] is S[Naϩ] in protein-free solution (meq/ kgH2O). Glomerular filtration rate (GFR) was estimated from creatinine clearance.
Data Analysis
For each subject, osmotic regulation of AVP was determined by plotting P[AVP] and thirst as functions of Posm during HSI. The sensitivity of P[AVP] or thirst to changes in Posm provides the slope of this relationship, and the intercept provides the threshold for P[AVP] release or thirst onset. Body water handling was determined through the assessment of overall fluid balance and the renal clearance of free water (CH 2 O), renal osmotic clearance (Cosm), and Na ϩ excretion. Statistics. The variables over time (control tests and hormone intervention tests) were analyzed by conditions (OCEP vs. OCP) using ANOVA for repeated measures. When significant differences were found, orthogonal contrasts tested differences between specific means related to the hypothesis of interest. Values are means Ϯ SE. Differences were considered statistically significant when P Ͻ 0.05 (BMPD Statistical Software, Los Angeles, CA).
Sample size calculation. Expected P [AVP] responses within and between groups are derived from data from our laboratory during HSI (28) . In an earlier study during HSI, the P[AVP]-Posm threshold decreased by 6 mosmol/kgH2O, with an estimated pooled standard deviation for the group of 3 mosmol/kgH2O.
The desired statistical test is two-sided at an ␣-level of 0.05 with 80% power to detect a difference. On the basis of our previous work, 80% power is sufficient to detect a significant alteration in P osm. For a two-sided test, Z(␣) ϭ 1.96, and for 
Substituting the values, the calculated sample size is eight subjects per group.
RESULTS
Baseline
One subject did not have estrogen and progesterone peaks in the midluteal phase, so her data were excluded from all analyses. Data on eight subjects are presented here.
Baseline P [E 2 ] and P [P 4 ] confirm that subjects were tested in the follicular and midluteal phases (Table 1 ; P Ͻ 0.05). Endogenous levels of 17␤-estradiol and progesterone were at follicular phase levels during oral contraceptive administration, as would be expected during exogenous estrogen-progesterone administration. During OCEP and OCP, ethinyl estradiol and norethindrone would be elevated to pharmacological levels in blood and tissue but were not measured by our assays. Preinfusion Hct was increased and estimated PV was reduced during the luteal phase compared with the follicular phase, OCP, and OCEP (Tables 1 and 2 ; P Ͻ 0.05). P osm was lower in the luteal phase and during OCEP than in the follicular phase ( Fig. 1 ; P Ͻ 0.05). However, P [AVP] was unaffected by menstrual phase or either oral contraceptive pill (Fig. 1) . Baseline P [Cort] was greater during OCEP than in all other conditions ( Fig. 1 ; P Ͻ 0.05).
Preinfusion P [Ald] was increased in the luteal phase relative to the follicular phase, although PRA was greater in the luteal phase, OCEP, and OCP than in the follicular phase ( Fig. 2 ; P Ͻ 0.05). U V , U osm , Na ϩ excretion, C H 2 O , and C osm were unaffected by phase or pill treatment, indicating that baseline hydration levels were similar among the treatment days (Table 3) . Although mean baseline U osm is greater than mean P osm during the follicular phase, OCP, and OCEP, C H 2 O is slightly above zero under these three conditions. These apparently inconsistent findings may be the result of variability in the subjects' U osm within each condition at baseline (82-858 mosmol/kgH 2 O) concomitant with only small mean differences in U osm among the conditions (Table 3 ). This anomaly led to fairly wide variability in U v (0.29-6.00 ml/min), C H 2 O (Ϫ2.02-4.31 ml/min), and C osm (3.46-0.57 ml/min) across the four conditions. Perhaps because of differences in the subjects' habitual water intake, the subjects' water intake (10 ml/kg body wt) on the morning of the tests did not fully hydrate some women but "over- hydrated" others. However, within each woman, the hydration levels were similar at baseline across all four tests.
Heart rate (73 Ϯ 3, 71 Ϯ 2, 70 Ϯ 2, and 69 Ϯ 3 beats/min) and mean blood pressure (82 Ϯ 2, 80 Ϯ 3, 76 Ϯ 2, and 76 Ϯ 3 mmHg) in the follicular and luteal phases, OCP, and OCEP, respectively, were also unaffected by menstrual cycle phase or by oral contraceptive treatment before HSI.
HSI
P osm during the luteal phase remained below that of the follicular phase and OCEP through the first 50 min of HSI ( Fig. 1 ; P Ͻ 0.05), although P [AVP] , percent PV change, and thirst were similar under all four conditions (Fig. 1, Table 2 ). Linear regression analysis of the individual subjects' data during HSI indicated significant correlations between P [AVP] and P osm (r ϭ 0.80 Ϯ 0.03) and thirst and P osm (r ϭ 0.90 Ϯ 0.02). The mean abscissal intercept for the P [AVP] -P osm relationship was greater in the follicular phase than in the luteal phase and OCEP (Fig. 3 , Table 1 ; P Ͻ 0.05). In contrast, the slopes of the P [AVP] -P osm and thirst-P osm relationships during HSI were unaffected by menstrual phase or oral contraceptive pills (Table 1 ). The regression line indicating the osmotic regulation of thirst and the slope of this relationship was unaffected by menstrual phase or oral contraceptive treatment (Table 1, Fig. 3 ).
PRA and P [Ald] decreased during HSI in all conditions, but only P [Ald] remained greater in the luteal phase than in the follicular phase ( Fig. 2 ; P Ͻ 0.05). During HSI, P [Cort] fell steadily in all conditions but remained greater with OCEP ( Fig. 1 ; P Ͻ 0.05). Renal Na ϩ and K ϩ excretion increased similarly during HSI in all conditions, as did C osm and C H 2 O (Table 3) . HSI had no effect on heart rate (69 Ϯ 2, 72 Ϯ 3, 72 Ϯ 2, and 68 Ϯ 2 beats/min) or mean blood pressure (83 Ϯ 4, 83 Ϯ 4, 83 Ϯ 3, and 81 Ϯ 4 mmHg) for follicular and luteal phase and OCP and OCEP, respectively under any of the four conditions. There were no treatment-by-time interactions for any of the blood, renal, or cardiovascular variables during HSI.
Recovery
P osm and percent change in PV were similar across conditions throughout recovery from HSI (Fig. 1, Table  1 ). Again, P [Cort] fell in all conditions but remained greater in OCEP than in the other three conditions ( Fig. 1; P Ͻ 0.05) . Although PRA was similar across menstrual cycle phases and oral contraceptive treatment, P [Ald] remained greater in the luteal phase than in the follicular phase, OCP, and OCEP ( Fig. 2 ; P Ͻ 0.05).
During the recovery period, neither renal function nor electrolyte excretion was affected by menstrual phase or oral contraceptive administration (Table 3) . Moreover, overall fluid balance (i.e., HSI ϩ drinking Ϫ urine output) was unaffected by either phase of the menstrual cycle or oral contraceptive administration (19 Ϯ 1, 19 Ϯ 1, 20 Ϯ 1, and 20 Ϯ 1 ml/kg body wt for follicular phase, luteal phase, OCP, and OCEP, respectively). Heart rate (68 Ϯ 3, 71 Ϯ 3, 75 Ϯ 2, and 70 Ϯ 3 beats/min) and mean blood pressure (78 Ϯ 2, 78 Ϯ 3, 78 Ϯ 3, and 76 Ϯ 3 mmHg) for follicular phase, luteal phase, OCP, and OCEP, respectively, during recovery were also not affected by menstrual cycle phase or oral contraceptive treatment. There were no treatment-bytime interactions for any of the blood, renal, or cardiovascular variables during recovery.
DISCUSSION
Our major finding was that administration of oral contraceptive pills containing estrogen with progesterone, but not pills containing progesterone alone, decreased the osmotic threshold for AVP release during HSI in young women. Our findings support previous studies in which AVP secretion persists during HSI at lower P osm at periods in the menstrual cycle corresponding to high P [E 2 ] , leading to lower renal free water excretion and maintenance of the lower plasma tonicity (27, 35, 37) . The present investigation extends these earlier findings demonstrating no independent effect of progesterone and indicates that this shift in osmotic regulation of AVP during OCEP and the luteal phase is primarily an estrogen-mediated effect. The shift in osmotically mediated AVP release occurred without excess fluid retention during HSI or recovery. Thus the estrogen-induced shift in osmotic regulation of AVP represents a shift in body water regulation to a lower P osm operating point or a resetting of osmoreceptors (30) . Moreover, although elevated estrogen and progesterone levels were associated with greater PRA and aldosterone, these increases in the Na ϩ -regulating hormones did not drive up blood pressure or Na ϩ retention. Finally, OCEP led to increases in P [Cort] before, during, and after HSI, although without any measurable metabolic or cardiovascular effects; this P [Cort] increase was likely due to changes in cortisol-binding protein induced by the synthetic hormones.
The estrogen-related shift in osmotic regulation of AVP release most likely occurs via the central nervous system. Estrogen acts directly on AVP-synthesizing neurons in the hypothalamus (1, 2, 6, 25) , and estrogen receptors have been identified in the nuclei of neurophysin-and AVP-producing cells in the mouse supraoptic nucleus (25) . There is also evidence of angiotensinergic innervation of vasopressinergic cells in the paraventricular and supraoptic nuclei, which are modulated by estrogen (31) . In addition, estrogen may impact AVP release indirectly via catecholamines (7) .
Progesterone administration without estrogen seemed to have little effect on osmotic regulation of AVP. In an earlier study, progesterone treatment increased the threshold and decreased the slope of the P [AVP] -P osm regression lines in women with premenstrual syndrome (38) . In our study, osmotic threshold for AVP release in OCP was similar to that in the luteal phase and OCEP. In addition, during OCP, there was a shift to a lower osmotic threshold for AVP release relative to the follicular phase in some, but not all, subjects. Taken together, these observations suggest an inconsistent effect of OCP on osmotic AVP regulation. There is evidence that progesterone receptor activity in the brain stimulates AVP production from the paraventricular nucleus, although this AVP stimulation by progesterone appears to depend on the presence of estrogen (3) . During the midluteal phase and during OCEP, estrogen concentrations in blood and tissue are greatly increased over follicular phase levels. Even though blood and tissue estrogen concentrations remained at follicular phase levels during OCP, follicular phase tissue levels of endogenous estrogen can vary considerably among individual women. Thus we can only speculate that subtle differences in hypothalamic endogenous estrogen levels among the subjects during OCP led to the variability in the P [AVP] response. The different P [AVP] responses to osmotic stimulation during the luteal phase vs. OCP may be due to structural or metabolic differences in endogenous progesterone vs. the synthetic progestin in OCP, norethindrone. Actions of progesterone in the brain may respond only to progesterone, and not to norethindrone, a progestational derivative of testosterone, which differs in structure from endogenous progesterone. Unlike endogenous progesterone, norethindrone does not produce the metabolite 3␣-hydroxydehydroprogesterone (11), a primary regulator of the GABA A receptor, which modulates a number of neural pathways (24) . Norethindrone metabolites may have similar effects on GABA A , and there is evidence indicating that oral contraceptives similar in structure to norethindrone increase GABA A levels in rat brain (8, 26) . However, progestin effects on GABA A have not been demonstrated in humans or in the hypothalamus of animals, so the impact on AVP release needs to be investigated further.
Although the most likely mechanism for the sex hormone-related shift in osmotic regulation of AVP is the central nervous system, peripheral mechanisms, such as changes in PV, also play an important role in the regulation of AVP release (23) . However, although changes in PV shift the P [AVP] -P osm response curve, in our study PV was decreased in the luteal phase but was increased during OCEP, despite similar reductions in the osmotic thresholds for AVP release. Furthermore, the difference in PV between the follicular phase and the luteal phase and between the follicular phase and OCEP (Ͻ10%) would have increased central venous pressure by Ͻ1 mmHg (15) , an insufficient change in central venous pressure to load cardiopulmonary baroreceptors enough to cause changes in the P osm -P [AVP] response curve (23) .
Corticotropin-releasing hormone and AVP interact at the level of the anterior pituitary (16), so we determined whether HSI induced a P [Cort] response. P [Cort] was greater only during OCEP relative to the other three experimental days, which is consistent with earlier studies and has been attributed to increases in cortisol-binding globulin (CBG) and associated with changes in the binding characteristics of cortisol to CBG during estrogen administration (5). Circulating cortisol is usually ϳ93-96% bound: ϳ83% to CBG and ϳ10% to albumin. However, during estrogen administration, cortisol binding can increase to ϳ99%, with the greater binding primarily to CBG. We attempted to measure differences in free P [Cort] across our four conditions using filters (Pall Filtron, Ann Arbor, MI) designed to separate free cortisol from its bound form. Once filtered, we found no differences in the free, biologically active portion of circulating cortisol among the different conditions. Thus the greater circulating cortisol should have had no significant physiological effects on our subjects. The decrease in P [Cort] over the course of the experiment in all four conditions was likely due to the normal circadian fall in cortisol release from its early morning peak to its later-day nadir.
Our data did not show a strong effect of estrogen or progesterone on the osmotic regulation of thirst. A study by Vokes et al. (37) demonstrated a 5 mosmol/ kgH 2 O fall in this threshold in the midluteal vs. the early follicular phase. We did not see any statistically significant effect of menstrual cycle or oral contraceptive pills on osmotic thirst regulation; however, we found trends showing that the thirst threshold fell from 286 mosmol/kgH 2 O in the follicular phase to 283 and 284 mosmol/kgH 2 O in the luteal phase and OCEP, respectively. Moreover, an earlier study also demonstrated a nonstatistically significant 3 mosmol/kgH 2 O fall in thirst onset during osmotic stimulation between the follicular and luteal phases of women with normal menstrual cycles (35) . Taken together, these studies suggest a small shift in the osmotic regulation of thirst. The difficulty in detecting these differences consistently may be a result of variability in the subjects' subjective interpretation of the thirst scales or subtle differences in the scales themselves (22) .
Arterial pressure also plays an important role in body fluid regulation, primarily by modulating Na ϩ excretion. During the luteal phase, a progesteronemediated inhibition of aldosterone-dependent Na ϩ reabsorption at distal sites in the nephron produces a transient natriuresis and a compensatory stimulation of the renin-aldosterone system (19) . The renin and aldosterone stimulation is a component of a system that evolved to maintain blood pressure and plasma water and Na ϩ content during the progesterone peak in the luteal phase. The progestin in OCEP and OCP (norethindrone), in contrast to endogenous progesterone, lacks antimineralocorticoid properties and did not increase P [Ald] , alter Na ϩ excretion, or increase blood pressure.
Our studies found a decrease in the osmotic threshold for AVP release during the administration of estrogen with progesterone, although there were no changes in osmotic regulation of AVP with progesterone administration alone. These data support the hypothesis that the observed changes in osmotic AVP regulation during the luteal phase and combined oral contraceptive administration are mediated by estrogen, most likely acting in the central nervous system. Thus mechanisms for the water retention and edema during periods of increased progesterone need to be addressed. Finally, the progestin in oral contraceptive pills differs structurally from endogenous progesterone; therefore, studies examining changes in body fluid distribution using the endogenous form of progesterone should be considered.
Perspectives
Alterations in the compartmentalization of fluid have important implications for a number of clinical conditions such as edema, hyponatremia, or hypertension. The relationships between sex hormones, fluid balance, and Na ϩ regulation play an important role in chronic conditions such as hypertension and other cardiovascular diseases. Progesterone fluctuations have been implicated as a primary cause of the cramping, water retention, and edema associated with premenstrual syndrome. In addition, estrogen and progesterone impact physiological responses to acute stress, such as heat stress and hyponatremia. Thus understanding the independent and combined mechanisms by which progesterone and estrogen affect body water regulation and Na ϩ regulation has implications for the treatment of a broad number of diseases.
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